Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Atherosclerosis|August 6, 2016
Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practiceAlberico L Catapano, Dominik Lautsch, Lale Tokgözoglu, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
The American Journal of Cardiology|October 21, 2016
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic HypercholesterolemiaPeter P Toth, Alberico L Catapano, Michel Farnier, et al.
Archives of Cardiovascular Diseases|May 18, 2024
Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of CardiologyFrançois Diévart, Eric Bruckert, Victor Aboyans, et al.
Archives of Cardiovascular Diseases|September 24, 2008
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial designJean-Marc Lablanche, Nicolas Danchin, Michel Farnier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 21, 2018
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 StudiesHenry N Ginsberg, Michel Farnier, Jennifer G Robinson, et al.
Journal of Clinical Lipidology|October 21, 2019
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapyPeter P Toth, Harold E Bays, W Virgil Brown, et al.
European Journal of Preventive Cardiology|October 15, 2025
Higher EPA levels and EPA/DHA Ratios Are associated with Lower Cardiovascular Mortality Post-Myocardial InfarctionDamien Leleu, Michel Farnier, Frédéric Chagué, et al.
Vascular Diseases (Paris, France)|May 27, 2026
Dosage of lipoproteins for risk management according to guidelinesChristophe Bonnin, Caroline Fourgeaud, Guillaume Mahé, et al.
Atherosclerosis|October 2, 2018
High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia RegistrySophie Béliard, Franck Boccara, Bertrand Cariou, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Atherosclerosis|August 6, 2016
Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practiceAlberico L Catapano, Dominik Lautsch, Lale Tokgözoglu, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
The American Journal of Cardiology|October 21, 2016
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic HypercholesterolemiaPeter P Toth, Alberico L Catapano, Michel Farnier, et al.
Archives of Cardiovascular Diseases|May 18, 2024
Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of CardiologyFrançois Diévart, Eric Bruckert, Victor Aboyans, et al.
Archives of Cardiovascular Diseases|September 24, 2008
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial designJean-Marc Lablanche, Nicolas Danchin, Michel Farnier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 21, 2018
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 StudiesHenry N Ginsberg, Michel Farnier, Jennifer G Robinson, et al.
Journal of Clinical Lipidology|October 21, 2019
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapyPeter P Toth, Harold E Bays, W Virgil Brown, et al.
European Journal of Preventive Cardiology|October 15, 2025
Higher EPA levels and EPA/DHA Ratios Are associated with Lower Cardiovascular Mortality Post-Myocardial InfarctionDamien Leleu, Michel Farnier, Frédéric Chagué, et al.
Vascular Diseases (Paris, France)|May 27, 2026
Dosage of lipoproteins for risk management according to guidelinesChristophe Bonnin, Caroline Fourgeaud, Guillaume Mahé, et al.
Atherosclerosis|October 2, 2018
High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia RegistrySophie Béliard, Franck Boccara, Bertrand Cariou, et al.
Pageof 15